Welcome to our dedicated page for Inhibitor Therap news (Ticker: INTI), a resource for investors and traders seeking the latest updates and insights on Inhibitor Therap stock.
Inhibitor Therapeutics, Inc. (OTCQB: INTI) is a biotechnology company developing itraconazole-based therapies for oncology, with a primary focus on basal cell carcinomas in patients with Basal Cell Carcinoma Nevus Syndrome (Gorlin Syndrome). This news page aggregates company announcements, clinical development updates, licensing milestones, and other disclosures that shed light on INTI’s progress.
Readers can find updates on the company’s itraconazole program, including results and analyses from its Phase 2b SCORING trial in BCCNS, where Inhibitor has reported clinically meaningful reductions in surgically eligible basal cell carcinoma lesions. News items also cover the work of the company’s Scientific Advisory Board, a group of experienced Mohs surgeons and dermatologic surgery experts who are reviewing trial outcomes to assess the clinical usefulness of itraconazole and its potential path toward regulatory filings.
In addition, the feed includes information on regulatory interactions such as the submission of a Pre-Investigational New Drug (PIND) application to the FDA and subsequent guidance received in preparation for an IND. Coverage of strategic agreements, such as the exclusive worldwide license with Johns Hopkins University for patents on "New Angiogenesis Inhibitors" and the master services agreement with Frameshift Management, Inc., provides context on how Inhibitor supports its development and regulatory strategy.
Investors and observers can use this page to follow categories of news that matter for a clinical-stage biotechnology company: clinical trial data, FDA-related steps, collaborations with academic and patient advocacy organizations, and material corporate agreements. For ongoing insight into INTI’s oncology pipeline and corporate actions, this page serves as a centralized view of its publicly released news.
Inhibitor Therapeutics, Inc. (OTCQB: INTI) has provided an update on its clinical development plan for an itraconazole formulation to treat Basal Cell Carcinomas in Gorlin Syndrome patients. The company has submitted a Pre-Investigational New Drug application (PIND) to the FDA and received preliminary comments. INTI has engaged Avior Bio to develop a new proprietary formulation of itraconazole, which will be bridged to the formulation used in their completed clinical study via a pharmacokinetic study.
The completed clinical study showed promising results, with 399 out of 477 targeted tumors showing reduction, 275 tumors (57.7%) achieving a clinically meaningful reduction of 30% or greater, and 130 tumors (27.3%) resolving completely. Inhibitor aims to submit an Investigational New Drug Application (IND) to the FDA by the end of Q1 2025.
FAQ
What is the current stock price of Inhibitor Therap (INTI)?
What is the market cap of Inhibitor Therap (INTI)?
